慢性肠系膜缺血血管内治疗患者死亡率改善
基于美国全国住院患者样本2000至2014年数据,共15,475例慢性肠系膜缺血住院患者,其中血管内治疗10,920例(70.6%)、开放手术4,555例(29.4%)。血管内治疗组死亡率、住院时间和费用均低于开放手术组。作者认为血管内治疗应被视为慢性肠系膜缺血的一线治疗。
要点
- 血管内治疗组住院死亡率2.4%,开放手术组8.7%(P < .0001)。
- 血管内治疗组平均住院6.3天,开放手术组14.0天(P < .0001)。
- 作者认为血管内治疗应被视为慢性肠系膜缺血患者的一线治疗。
核心结论
- 校正临床和医院因素后,血管内治疗组住院死亡率、住院时间和费用均低于开放手术组,作者认为血管内治疗应被视为慢性肠系膜缺血的一线治疗。
研究设计与样本
- 基于美国全国住院患者样本(NIS)2000至2014年数据,纳入所有因慢性肠系膜缺血(CMI)住院的患者,共15,475例,平均年龄71岁,男性4,022例(26.0%)。
主要发现
- 血管内治疗组10,920例(70.6%),开放手术组4,555例(29.4%)。
- 血管内治疗组Charlson合并症指数评分≥2的比例为43.3%,开放手术组为33.1%(P < .0001)。
- 血管内治疗组死亡率2.4%,开放手术组8.7%(P < .0001);血管内治疗组平均住院时间6.3天,开放手术组14.0天(P < .0001);血管内治疗组平均住院费用21,686美元,开放手术组42,974美元(P < .0001)。
- 校正临床和医院因素后,开放手术组死亡率仍高于血管内治疗组(比值比7.2;95%置信区间4.9-10.6;P < .0001),住院时间平均延长9.7天(P < .0001),住院费用平均增加25,834美元(P < .0001)。
临床怎么用
- 作者认为,对于慢性肠系膜缺血患者,血管内治疗应被视为一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic mesenteric ischemia (CMI) continues to be a devastating diagnosis. There is a national trend toward increased use of endovascular procedures with improved survival for the treatment of these patients. Our aim was to evaluate whether this trend has changed CMI patients' length of hospitalization and health care cost. METHODS: We identified all patients admitted for CMI from the National Inpatient Sample (NIS) from 2000 to 2014. Our primary end points included length of hospital stay (LOS) and cost of hospitalization (COH). Our secondary end points included mortality assessment of the CMI hospitalization. RESULTS: There were 15,475 patients admitted for CMI. The mean age of patients was 71 years, and 4022 (26.0%) were male. There were 10,920 (70.6%) patients treated endovascularly (ENDO) and 4555 (29.4%) patients treated in an open fashion (OPEN). Although a higher proportion of patients in the ENDO (43.3%) group vs OPEN (33.1%) had a Charlson Comorbidity Index score of ≥2 (P < .0001), they had a lower mortality rate (2.4% vs 8.7%; P < .0001), lower mean LOS (6.3 vs 14.0 days; P < .0001), and lower COH ($21,686 vs $42,974; P < .0001). After adjusting for clinical and hospital factors, OPEN continued to demonstrate higher mortality than ENDO (odds ratio, 7.2; 95% confidence interval, 4.9-10.6; P < .0001), longer LOS (mean, +9.7 days; P < .0001), and higher COH (mean, +$25,834; P < .0001). CONCLUSIONS: The rate of ENDO continues to rise nationally in the treatment of CMI patients. After adjusting for clinical and hospital factors, patients in the ENDO group tend to have lower in-hospital mortality of 2.4% and lower LOS by 10 days, and they incur a cost saving of >$25,000 compared with patients in the OPEN group. ENDO should be considered first line of therapy for patients with CMI.
引用
- Erben Y, Jean RA, Protack CD, et al. Improved mortality in treatment of patients with endovascular interventions for chronic mesenteric ischemia. J Vasc Surg. 2018. PMID: 29395425. doi:10.1016/j.jvs.2017.10.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。